Novartis acquired global rights to Xiidra (lifitegrast), an approved treatment for dry eye disease, from Takeda (which inherited the asset from its Shire acquisition). Novartis paid $3.4B upfront plus up to $1.9B in milestones. This was part of Takeda's post-Shire divestiture strategy to reduce debt.